These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 2960431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
    Markham A, Benfield P.
    CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
    [Abstract] [Full Text] [Related]

  • 3. Management of levodopa failures: the use of dopamine agonists.
    Lieberman AN, Gopinathan G, Neophytides A, Goldstein M.
    Clin Neuropharmacol; 1986 Apr; 9 Suppl 2():S9-21. PubMed ID: 3297319
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of pergolide and mesulergine.
    Lieberman AN, Gopinathan G, Neophytides A.
    Eur Neurol; 1986 Apr; 25(2):86-90. PubMed ID: 3948891
    [Abstract] [Full Text] [Related]

  • 5. The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.
    Lieberman AN, Leibowitz M, Gopinathan G, Walker R, Hiesiger E, Nelson J, Goldstein M.
    Am J Med Sci; 1985 Sep; 290(3):102-6. PubMed ID: 4050844
    [Abstract] [Full Text] [Related]

  • 6. MK 458, a selective and potent D2 receptor agonist in advanced Parkinson's disease.
    Lieberman A, Chin L, Baumann G.
    Clin Neuropharmacol; 1988 Jun; 11(3):191-200. PubMed ID: 2900065
    [Abstract] [Full Text] [Related]

  • 7. Bromocriptine in Parkinson disease.
    Lieberman AN, Goldstein M.
    Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
    [Abstract] [Full Text] [Related]

  • 8. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

  • 9. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
    Radad K, Gille G, Rausch WD.
    Pharmacol Rep; 2005 May; 57(6):701-12. PubMed ID: 16382188
    [Abstract] [Full Text] [Related]

  • 10. Dopamine agonists as primary treatment in Parkinson's disease.
    Rinne UK.
    Adv Neurol; 1987 May; 45():519-23. PubMed ID: 3103394
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of Parkinson's disease with 8-alpha-amino-ergoline, CU 32-085.
    Schneider E, Hubener K, Fischer PA.
    Neurology; 1983 Apr; 33(4):468-72. PubMed ID: 6682193
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Should dopamine agonists be given early or late? A review of nine years experience with bromocriptine.
    Lieberman AN, Gopinathan G, Hassouri H, Neophytides A, Goldstein M.
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):233-7. PubMed ID: 6713322
    [Abstract] [Full Text] [Related]

  • 14. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A, Neophytides A, Kupersmith M, Casson I, Durso R, Foo SH, Khayali M, Tartaro T, Goldstein M.
    Am J Med Sci; 1979 Feb; 278(1):65-76. PubMed ID: 39452
    [Abstract] [Full Text] [Related]

  • 15. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE.
    Experientia; 1984 Nov 15; 40(11):1165-72. PubMed ID: 6437857
    [Abstract] [Full Text] [Related]

  • 16. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Nov 15; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 17. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN, Gopinathan G, Neophytides A, Leibowitz M, Goldstein M.
    Adv Neurol; 1984 Nov 15; 40():503-7. PubMed ID: 6695627
    [Abstract] [Full Text] [Related]

  • 18. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Walker R, Pact V.
    Clin Pharmacol Ther; 1982 Jul 15; 32(1):70-5. PubMed ID: 7083733
    [Abstract] [Full Text] [Related]

  • 19. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G, Spanish Dopamine Agonists Study Group.
    Clin Neuropharmacol; 2008 Jul 15; 31(1):19-24. PubMed ID: 18303487
    [Abstract] [Full Text] [Related]

  • 20. Dopamine agonists in Parkinson's disease.
    Calne DB, Burton K, Beckman J, Martin WR.
    Can J Neurol Sci; 1984 Feb 15; 11(1 Suppl):221-4. PubMed ID: 6231979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.